Company intelligence / Profile preview

Autotransport

London, England, United Kingdomautotransport.com ↗

Ownership: Private
Development stage: Other

Overview

Autolus is a clinical-stage biopharmaceutical company developing advanced autologous T cell therapies using proprietary programming and manufacturing technologies. Its lead candidate, obe-cel, targets relapsed/refractory adult acute lymphoblastic leukemia and is progressing through late-stage clinical trials. The company has a pipeline addressing hematological cancers, solid tumors, and autoimmune diseases.

Therapeutic areas: OncologyImmunology
Modalities: CAR-T cell therapyCell therapy
Industry: Biotech

Partnerships

BioNTech – strategic alliance for CAR-T development and manufacturing access

Beyond the preview

Go deeper on Autotransport.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Autotransport.

Explore the full profile